HomeIndustriesTechnologyEli Lilly (LLY) Hits High After Diabetes Drug Approval

Eli Lilly (LLY) Hits High After Diabetes Drug Approval

Eli Lilly (LLY) is higher after Chinese regulators approve diabetes drug in China. Diane King Hall discusses this as Eli Lilly’s Phase 3 study of Crohn’s disease treatment achieves “meaningful improvements.” Eli Lilly hit a new all-time high today. Tune in to find out more about the stock market today.

Next Gen Investing

21 May 2024

SHARE

ON AIR
7:00 pm
Market On Close
education
5:00 am
Your First Trade
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
The Wrap
REPLAY
education
7:00 am
Your First Trade
REPLAY
education
7:30 am
Your First Trade
REPLAY
8:00 am
Market Overtime
REPLAY
9:00 am
Market Overtime
REPLAY
education
9:30 am
Inside the Mind of a Trader
REPLAY
education
10:00 am
Inside the Mind of a Trader
REPLAY
education
10:30 am
Inside the Mind of a Trader
REPLAY
11:00 am
The Wrap
REPLAY
12:00 pm
Morning Movers
1:00 pm
Morning Trade Live
3:00 pm
Trading 360
4:00 pm
Fast Market
5:00 pm
Next Gen Investing
6:00 pm
The Watch List
ON AIR
7:00 pm
Market On Close
8:30 pm
Market Overtime
REPLAY
9:30 pm
Market Overtime
REPLAY
10:00 pm
Next Gen Investing
REPLAY
11:00 pm
The Wrap
REPLAY
12:00 am
Market Overtime
REPLAY
1:00 am
The Wrap
REPLAY
2:00 am
Market Overtime
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY

Schwab Network's Newsletters

Daily insights for every investor